| Accession |
PRJCA011668 |
| Title |
A Phase I, Open-Label, Multicenter Study to Assess Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced NSCLC patients with EGFR or HER2 Mutations |
| Relevance |
Medical |
| Data types |
Variation
|
| Organisms |
Homo sapiens
|
| Description |
This study includes dose escalation and dose expansion parts. Dose expansion was triggered at dose levels that anti-tumor efficacy was observed in EGFR Exon20ins or HER2 Exon20ins patients. The primary objective is to evaluate safety and tolerability and define MTD and RP2D. |
| Sample scope |
Single cell |
| Release date |
2023-06-30 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
mengzhao
wang (mengzhaowang@sina.com)
|
| Organization |
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College |
| Submission date |
2022-09-05 |
